Limb-Girdle Muscular Dystrophy (LGMD) Cell Models for Research

Limb-girdle muscular dystrophy (LGMD) comprises a genetically heterogeneous group of inherited muscle disorders with an estimated global prevalence of 1 in 14,500 to 1 in 123,000, depending on population and diagnostic criteria (Orphanet, 2023; WHO, 2023). The LGMD subtypes are classified into autosomal dominant (LGMD D1-D5) and autosomal recessive (LGMD R1-R28) forms, with over 30 causative genes identified (NCBI Gene, 2024).

Key clinical features include progressive weakness and wasting of proximal limb-girdle muscles, elevated serum creatine kinase (CK), and dystrophic changes on muscle biopsy. Cardiac and respiratory involvement occurs in specific subtypes, notably LGMD R1 (calpainopathy), LGMD R2 (dysferlinopathy), and LGMD R9 (FKRP-related).

There is no cure for LGMD. Management is supportive, including physiotherapy, corticosteroids (in some subtypes), and respiratory support. Five-year survival is generally >90% for ambulatory patients but drops to approximately 50-70% in advanced stages with cardiac or respiratory failure (NCI, 2023; Muscular Dystrophy Association, 2023).

Risk factors are primarily genetic. Autosomal recessive forms require biallelic pathogenic variants, while dominant forms arise from heterozygous mutations. Consanguinity increases risk for recessive subtypes. No environmental or lifestyle risk factors have been established.

LGMD is an attractive model for mechanistic and therapeutic studies due to its well-defined genetic architecture, accessible muscle biopsies, and the availability of patient-derived cells. The disease affects a core tissue (skeletal muscle) with conserved biology across species, enabling translation from cell and animal models to humans.

Key research advantages:

• • Subtype-specific genetics: Over 30 genes with distinct functions (sarcomeric, sarcolemmal, enzymatic) allow dissection of convergent and divergent pathogenic pathways.
• • Public datasets: Resources such as ClinVar, gnomAD, and the Leiden Muscular Dystrophy pages provide curated variant data.
• • Open questions: How do different mutations in the same gene produce variable phenotypes? What are the earliest molecular events? Can gene editing restore function?
• • Therapeutic relevance: LGMD is a target for gene therapy, exon skipping, and small-molecule correctors, requiring robust preclinical models.

Gene-edited cell models (knockouts, knock-ins, isogenic lines) are essential to link specific mutations to molecular and cellular phenotypes, and to test targeted interventions.

LGMD is not a cancer, but its pathogenesis involves several key molecular pathways that can be modeled in gene-edited cells. These pathways are not carcinogenic but are critical for muscle integrity and function.

1. Sarcolemmal stability and membrane repair:

• • Dystrophin-glycoprotein complex (DGC) links the cytoskeleton to the extracellular matrix.
• • Mutations in SGCA, SGCB, SGCG, SGCD (sarcoglycanopathies) disrupt the DGC, leading to membrane fragility.
• • Dysferlin (DYSF) is required for calcium-dependent membrane repair; its loss causes LGMD R2.

2. Calpain-mediated proteolysis:

• • CAPN3 encodes calpain-3, a calcium-dependent protease in skeletal muscle.
• • Mutations in CAPN3 (LGMD R1) lead to loss of proteolytic regulation, sarcomere disorganization, and apoptosis.

3. Glycosylation defects:

• • FKRP, POMT1, POMT2, POMGNT1, and other genes affect alpha-dystroglycan glycosylation.
• • Hypoglycosylation of alpha-dystroglycan disrupts laminin binding, causing LGMD R9 and related dystroglycanopathies.

4. Nuclear envelope and sarcomere maintenance:

• • LMNA, TMEM43, and other genes affect nuclear envelope integrity and mechanotransduction.
• • TTN, MYOT, and LMNA mutations impair sarcomere assembly and force transmission.

These pathways are interrogated using knockout and knock-in cell models to identify early pathogenic events and therapeutic targets.

The table below summarizes the most common LGMD subtypes, their causative genes, approximate relative frequencies, mutation types, and functional effects. Data are compiled from ClinVar, gnomAD, and published cohort studies (e.g., Norwood et al., 2020; ClinVar, 2024).

Note: Frequencies vary by population and diagnostic criteria. Data from ClinVar (2024) and gnomAD (2024).

LGMD pathogenesis involves dysregulation of several signaling networks that can be studied in gene-edited cell models. Key nodes include:

• • Calcium signaling:
• • CAPN3, DYSF, and ANO5 mutations alter intracellular calcium handling.
• • Dysregulated calcium activates proteases (calpains) and induces apoptosis.
• • Mechanotransduction:
• • LMNA and DGC components link mechanical stress to nuclear signaling.
• • YAP/TAZ and MEF2 pathways are affected in laminopathies and sarcoglycanopathies.
• • Autophagy and proteostasis:
• • Impaired autophagy contributes to protein aggregate accumulation in LGMD R1 and R2.
• • mTOR signaling is altered in response to metabolic stress.
• • Inflammatory and fibrotic pathways:
• • NF-kB and TGF-beta signaling promote chronic inflammation and fibrosis.
• • Macrophage infiltration and cytokine release (IL-6, TNF-alpha) exacerbate muscle damage.
• • Regeneration and satellite cell function:
• • Notch and Wnt signaling regulate satellite cell activation.
• • LGMD mutations impair regenerative capacity, leading to fibrofatty replacement.

These networks are interrogated using CRISPR knockout and knock-in models to identify points of intervention.

Several cell lines and organoid models are used to study LGMD. The table below lists commonly used lines, their origin, and key mutations.

Organoid advantages: 3D muscle organoids derived from patient iPSCs recapitulate muscle architecture, enable long-term culture, and allow functional assays (contraction, calcium imaging). They are valuable for studying fibrosis and regeneration.

Note: Many of these lines are available from commercial and academic sources. Gene-edited versions are increasingly used to isogenically control for genetic background.

Animal models are essential for LGMD research. Key models include:

• • Spontaneous models:
• • SJL/J mouse (dysferlinopathy; DYSF mutation).
• • Mdx mouse (dystrophinopathy; not LGMD but related).
• • Genetically engineered models (GEMM):
• • CAPN3 knockout mouse (LGMD R1).
• • SGCA knockout mouse (LGMD R3).
• • FKRP knock-in mouse (LGMD R9; L276I).
• • LMNA knockout mouse (laminopathy).
• • Induced models:
• • CRISPR-generated rat and pig models for LGMD R1 and R2.
• • Zebrafish models for glycosylation defects (FKRP, POMT1).
• • Patient-derived xenografts (PDX):
• • Rare for LGMD due to non-cancerous nature; however, patient-derived myoblast xenografts in immunodeficient mice can assess regeneration.

These models are used for preclinical efficacy and safety studies. Gene-edited cell models complement animal work by enabling high-throughput screening and mechanistic dissection.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines that differ only at the targeted locus, eliminating confounding genetic background effects. For LGMD, key models include:

• • Knockout lines:
• • CAPN3 knockout in C2C12 or patient iPSCs to model LGMD R1.
• • DYSF knockout in myoblasts to study membrane repair defects.
• • SGCA knockout to disrupt the sarcoglycan complex.
• • Knock-in lines:
• • FKRP L276I knock-in in iPSCs to model LGMD R9.
• • CAPN3 missense mutations (e.g., R448H) to study partial loss-of-function.
• • ANO5 mutations (e.g., c.191dupA) to model LGMD R12.
• • Reporter lines:
• • Fluorescent reporters for CAPN3 or DYSF to monitor expression and localization.
• • Calcium-sensitive reporters (GCaMP) to assess calcium handling.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing ready-to-use, reproducible tools. These models are validated for target gene knockout or knock-in, off-target analysis, and functional readouts. They enable researchers to focus on biology rather than model generation.

Examples of applications:

• • Isogenic pairs (wild-type vs. mutant) for drug screening.
• • Tagged lines for proteomics and interactomics.
• • Dual-reporter lines for high-content imaging.

Such models are available from commercial sources without naming specific companies.

Gene-edited cell models are powerful tools for functional genomics in LGMD. Knockout and knock-in lines allow researchers to:

• • Validate candidate genes: CRISPR knockout of CAPN3, DYSF, or SGCA confirms their role in muscle integrity.
• • Dissect domain functions: knock-in of specific missense mutations (e.g., FKRP L276I) reveals effects on glycosylation and laminin binding.
• • Study gene dosage: heterozygous knockouts model carrier states.
• • Perform saturation genome editing: tiling mutations across a gene to map functional domains.

Examples:

• • A CAPN3 knockout myoblast line shows impaired sarcomere assembly and increased apoptosis.
• • A DYSF knockout line exhibits defective membrane repair after laser injury.
• • An SGCA knock-in line with a patient mutation shows reduced sarcoglycan complex formation.

These models enable high-throughput screens (e.g., CRISPR libraries) to identify modifiers and synthetic lethal interactions.

Isogenic gene-edited cell pairs are ideal for drug screening and resistance studies. Key applications:

• • Isogenic pair screens: Compare wild-type and mutant lines to identify compounds that selectively rescue mutant phenotypes.
• • Resistance modeling: Generate resistant lines by chronic drug exposure and compare with parental lines to identify resistance mechanisms.
• • Combination screens: Test drug combinations in knockout lines to uncover synergistic targets.

Examples:

• • A CAPN3 knockout line can be used to screen for calpain activators or proteasome inhibitors.
• • A FKRP knock-in line can be used to screen for glycosylation correctors.
• • A DYSF knockout line can be used to screen for membrane stabilizers.

Gene-edited models provide a reproducible platform for high-throughput screening and mechanism-of-action studies.

CRISPR screens in gene-edited cells enable biomarker discovery for LGMD. Approaches include:

• • Synthetic lethality screens: Identify genes that are essential only in the presence of an LGMD mutation.
• • Resistance screens: Identify genes whose knockout confers resistance to a drug.
• • Reporter-based screens: Use fluorescent reporters (e.g., CAPN3-GFP) to monitor protein stability and localization.

Examples:

• • A genome-wide CRISPR knockout screen in a DYSF mutant line identified modifiers of membrane repair.
• • A focused screen in a CAPN3 knockout line revealed synthetic lethal interactions with autophagy genes.
• • A reporter line for FKRP glycosylation enabled screening for compounds that restore alpha-dystroglycan function.

These screens yield candidate biomarkers and therapeutic targets, which can be validated in patient samples.

The following public databases provide valuable data for LGMD research. All URLs are real and accessible.

Note: TCGA, COSMIC, and DepMap are cancer-focused but can provide cell line and gene expression data relevant to muscle biology. For LGMD-specific data, ClinVar, gnomAD, and Leiden databases are most relevant.